Search Results - therapeuticarea+%3e+immunology

182 Results

Sort By:

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...

Published: 9/13/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Interleukin-27 Producing B-Cell Population and Uses Thereof

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host...

Published: 8/14/2024 | Inventor(s): Charles Egwuagu, Jin Choi

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Eye / Ear / Nose / Throat, TherapeuticArea > Neurology, TherapeuticArea > Immunology

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Published: 7/26/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

PET Imaging of lntegrin Expression with Suitably Labeled RGD Peptides for Multiple Diagnostic Purposes

This technology includes a number of dimeric RGD peptides which been developed and labeled with various PET isotopes (1BF, 68Ga, and 64Cu) for imaging integrin expression in cancer, inflammation, rheumatoid arthritis, myocardial infarct, stroke and traumatic injury. A number of these peptides have been translated into clinic for diagnosis and therapy...

Published: 8/12/2024 | Inventor(s): Xiaoyuan (Shawn) Chen, Lixin Lang, Gang NIU

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Cardiology, TherapeuticArea > Immunology, TherapeuticArea > Neurology

Use of Regulatory Genetic Variants of IL 1 RN to Guide Therapeutic Decision Making in Systemic Juvenile Idiopathic Arthritis Patients

This technology includes the use of genetic markers to predict the response of patients, particularly children with systemic juvenile idiopathic arthritis (sJiA), to anakinra treatment. Anakinra is a human recombinant IL-1 RA used in treating sJiA, a severe childhood inflammatory disease where early and effective treatment is essential for better long-term...

Published: 7/30/2024 | Inventor(s): Michael Ombrello

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, TherapeuticArea > Immunology

Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery

This technology includes mouse models that express versions of mouse cryopyrin protein containing mutations associated with human CAPS disease. We engineered mutations associated with three specific CAPS phenotypes (familial cold autoinflammatory syndrome (FCAS); Muckle-Wells syndrome (MWS); and neonatal onset multisystem inflammatory disease (NOMID))...

Published: 8/12/2024 | Inventor(s): Susannah Brydges, Harold Hoffman, Daniel Kastner, James Mueller

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Immunology

Monoclonal Anti-mouse and Anti-human TL 1A Antibodies for Diagnostic and Therapeutic Utilization

This technology includes antibodies against TL 1A for the inhibition of TL 1A-DR3 interactions for the diagnosis and treatment of various autoimmune diseases. Through the use of our developed hamster anti-mouse and mouse anti-human monoclonal antibodies, we’ve demonstrated that treatment with anti-mouse TL 1A prevented collagen-induced arthritis...

Published: 7/30/2024 | Inventor(s): Richard Siegel, Francoise Meylan, Yun-Jeong Song

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology

Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus

This technology includes a small molecule drug (VDAC inhibitor, also known as VBIT4) that may be useful for inhibiting lupus disease. To test lupus animal model, VBIT4 was continuously administered for 5 weeks to mice and there was no mortality or clinical symptoms in these animals. Additionally, VBIT4 treatment blocked the development of skin lesions...

Published: 8/12/2024 | Inventor(s): Jeonghan Kim, Jay Chung, Varda Shoshan-barmatz

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Immunology

Cycioxygenase-2 Inhibition for the Treatment-SAA-high Asthma

This technology includes the use of cyclooxygenase-2 (COX-2) inhibitors for the treatment of serum amyloid A (SAA)-high asthma. A commercially available enzyme-linked immunosorbent assay was used to analyze serum levels of SAA in a cohort of 154 non-asthmatic subjects to establish the upper 95th centile value of serum SAA in healthy individuals as >...

Published: 9/11/2024 | Inventor(s): Stewart Levine, Xianglan Yao, Alan Remaley, Amisha Barochia, Maryann Kaler

Keywords(s):

Category(s): Application > Diagnostics, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Respiratory

Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions

This technology includes the creation and use of A3 adenosine receptor (A3AR)-selective agonists for treating chemotherapy-induced peripheral neuropathy, chronic neuropathic pain, rheumatoid arthritis, psoriasis, and other conditions. A3 receptors for adenosine are found in most cells and endogenous activation of the A3 receptors can result in apoptosis,...

Published: 8/12/2024 | Inventor(s): Daniela Salvemini, Dilip Tosh, Kenneth Jacobson

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Oncology

1 2 3 4 5 6 7 8 9 10 ...